Therapeutic Targeting of Mesothelin with Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia

PURPOSE: We previously identified mesothelin (MSLN) as highly expressed in a significant fraction of acute myeloid leukemia (AML) but entirely silent in normal hematopoiesis, providing a promising antigen for immunotherapeutic targeting that avoids hematopoietic toxicity. Given that T cells genetica...

Descripción completa

Detalles Bibliográficos
Autores principales: Le, Quy, Castro, Sommer, Tang, Thao, Loeb, Anisha M., Hylkema, Tiffany, McKay, Cyd Nourigat, Perkins, LaKeisha, Srivastava, Shivani, Call, Lindsey, Smith, Jenny, Leonti, Amanda, Ries, Rhonda, Pardo, Laura, Loken, Michael R., Correnti, Colin, Fiorenza, Salvatore, Turtle, Cameron J., Riddell, Stanley, Tarlock, Katherine, Meshinchi, Soheil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
Translational Cancer Mechanisms and Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401532/
https://www.ncbi.nlm.nih.gov/pubmed/34380639
http://dx.doi.org/10.1158/1078-0432.CCR-21-1546

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401532/
https://www.ncbi.nlm.nih.gov/pubmed/34380639
http://dx.doi.org/10.1158/1078-0432.CCR-21-1546

Ejemplares similares